Tourmaline Bio (TRML) News Today $16.84 -0.28 (-1.64%) Closing price 04:00 PM EasternExtended Trading$17.94 +1.10 (+6.53%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $53.14 Consensus Price Target from AnalystsMarch 19, 2025 | americanbankingnews.comTourmaline Bio (NASDAQ:TRML) Price Target Raised to $43.00 at WedbushMarch 16, 2025 | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by AnalystsShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned a consensus rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year priMarch 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Given New $43.00 Price Target at WedbushWedbush upped their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday.March 15, 2025 | marketbeat.comTOURMALINE BIO Earnings Results: $TRML Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comTourmaline Bio (TRML) Gets a Buy from WedbushMarch 15, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright increased their price target on shares of Tourmaline Bio from $49.00 to $50.00 and gave the company a "buy" rating in a research report on Friday.March 15, 2025 | marketbeat.comTourmaline Bio price target raised to $43 from $42 at WedbushMarch 14, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPSTourmaline Bio (NASDAQ:TRML - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.05.March 14, 2025 | marketbeat.comTourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 14, 2025 | finanznachrichten.deTourmaline Bio reports Q4 EPS (86c), consensus (87c)March 14, 2025 | markets.businessinsider.comTourmaline Bio shares fall as Q4 loss widensMarch 14, 2025 | investing.comTourmaline Bio sees cash runway into 2H27March 14, 2025 | markets.businessinsider.comTourmaline Bio’s 2024 Financial Results and Strategic AdvancesMarch 14, 2025 | tipranks.comTourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial OutlookMarch 13, 2025 | quiverquant.comTourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 13, 2025 | globenewswire.comTourmaline Bio (TRML) Projected to Post Earnings on TuesdayTourmaline Bio (NASDAQ:TRML) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)March 10, 2025 | markets.businessinsider.comWedbush Forecasts Tourmaline Bio FY2024 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued to investors on Thursday, March 6th. Wedbush analyst L. Chico anticipates that the company will earn ($2.78) per share for the year. WedbMarch 10, 2025 | marketbeat.comWedbush bullish on Tourmaline Bio, initiates with an OutperformMarch 7, 2025 | markets.businessinsider.comWedbush Initiates Coverage of Tourmaline Bio (TRML) with Outperform RecommendationMarch 7, 2025 | msn.comTourmaline Bio (NASDAQ:TRML) Earns Outperform Rating from Analysts at WedbushWedbush assumed coverage on shares of Tourmaline Bio in a research report on Thursday. They issued an "outperform" rating and a $42.00 price objective for the company.March 7, 2025 | marketbeat.comTourmaline Bio initiated with an Outperform at WedbushMarch 6, 2025 | markets.businessinsider.comTourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025March 3, 2025 | globenewswire.comTruist Financial Sticks to Their Buy Rating for Tourmaline Bio (TRML)February 27, 2025 | markets.businessinsider.comLifesci Capital Estimates Tourmaline Bio FY2024 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Tourmaline Bio in a report issued on Monday, February 24th. Lifesci Capital analyst R. Katkhuda anticipates that the company will earn ($2.89) perFebruary 26, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform RecommendationFebruary 25, 2025 | msn.comTourmaline Bio initiated with an Outperform at LifeSci CapitalFebruary 24, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Now Covered by Analysts at Lifesci CapitalLifesci Capital started coverage on Tourmaline Bio in a research report on Monday. They set an "outperform" rating and a $58.00 price target for the company.February 24, 2025 | marketbeat.comTourmaline Bio management to meet with TruistFebruary 19, 2025 | msn.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by AnalystsShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-monFebruary 19, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Sees Large Growth in Short InterestTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 16.3% from the January 15th total of 2,330,000 shares. Based on an average trading volume of 248,100 shares, the days-to-cover ratio is currently 10.9 days. Currently, 17.4% of the shares of the stock are sold short.February 16, 2025 | marketbeat.comLeerink Partnrs Raises Earnings Estimates for Tourmaline BioTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.83February 10, 2025 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio FY2029 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company willFebruary 7, 2025 | marketbeat.comJennison Associates LLC Has $17.15 Million Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Jennison Associates LLC lessened its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 26.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 845,800 shares of the company's stock after selling 306,1February 6, 2025 | marketbeat.comTourmaline Bio management to meet with Cantor FitzgeraldFebruary 5, 2025 | markets.businessinsider.comTourmaline Bio, Inc. (NASDAQ:TRML) Short Interest UpdateTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,080,000 shares, an increase of 26.8% from the December 31st total of 1,640,000 shares. Approximately 13.8% of the shares of the company are sold short. Based on an average trading volume of 197,500 shares, the days-to-cover ratio is presently 10.5 days.January 31, 2025 | marketbeat.comTourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 27, 2025 | markets.businessinsider.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from BrokeragesTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts thatJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Comments on Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tourmaline Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn (January 22, 2025 | marketbeat.comShort Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Rises By 26.8%Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,080,000 shares, an increase of 26.8% from the December 15th total of 1,640,000 shares. Based on an average trading volume of 197,500 shares, the short-interest ratio is currently 10.5 days. Currently, 13.8% of the shares of the company are short sold.January 16, 2025 | marketbeat.comBarclays PLC Has $819,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Barclays PLC raised its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 283.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,833 shares of the company's stock after purchasingJanuary 16, 2025 | marketbeat.comTourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. RidkerJanuary 10, 2025 | globenewswire.comTourmaline Bio: Promising Cardiovascular and Innovative Indications Drive Buy Rating Amid Upcoming Data MilestonesJanuary 8, 2025 | markets.businessinsider.comTourmaline Bio, Inc. (NASDAQ:TRML) Position Lifted by Geode Capital Management LLCGeode Capital Management LLC grew its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,078 shares of the comJanuary 1, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of "Buy" by AnalystsTourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given a consensus rating of "Buy" by the six ratings firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objectDecember 31, 2024 | marketbeat.comState Street Corp Has $10.59 Million Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)State Street Corp lifted its holdings in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 411,980 shares of the company's stock after acquirDecember 27, 2024 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Down 3.9% - Should You Sell?Tourmaline Bio (NASDAQ:TRML) Shares Down 3.9% - Should You Sell?December 24, 2024 | marketbeat.comFmr LLC Has $387,000 Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Fmr LLC decreased its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 93.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,063 shares of the company's stock afterDecember 20, 2024 | marketbeat.comWellington Management Group LLP Raises Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)Wellington Management Group LLP raised its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 72.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,741 shares of the company's stock aftDecember 19, 2024 | marketbeat.com Remove Ads Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Media Mentions By Week TRML Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRML News Sentiment▼0.930.89▲Average Medical News Sentiment TRML News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRML Articles This Week▼12▲TRML Articles Average Week Remove Ads Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vera Therapeutics News Galapagos News Kiniksa Pharmaceuticals News Schrödinger News Ascentage Pharma Group International News IDEAYA Biosciences News Wave Life Sciences News Immunocore News ANI Pharmaceuticals News Dyne Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRML) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRML Stock Free TRML Stock Alerts